Nonalcoholic fatty liver disease (NAFLD) represents the hepatic manifestation of metabolic syndrome. The aim of this pilot study was to evaluate the effect of orlistat, a drug used in the obesity treatment, in association to diet regimen compared to only diet in obese patients with ultrasonographic diagnosis of NAFLD. Preliminary results underline the relevance of ultrasonography to make diagnosis and staging of NAFLD. It could be suggested that orlistat has a positive effect in the prevention of metabolic and cardiovascular complications associated with obesity.
Effetto di Orlistat sulla steatopatia non alcolica nei pazienti obesi
CENA, HELLAS;ROGGI, CARLA;
2007-01-01
Abstract
Nonalcoholic fatty liver disease (NAFLD) represents the hepatic manifestation of metabolic syndrome. The aim of this pilot study was to evaluate the effect of orlistat, a drug used in the obesity treatment, in association to diet regimen compared to only diet in obese patients with ultrasonographic diagnosis of NAFLD. Preliminary results underline the relevance of ultrasonography to make diagnosis and staging of NAFLD. It could be suggested that orlistat has a positive effect in the prevention of metabolic and cardiovascular complications associated with obesity.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
